VISCHER advises ProteoMediX Raises in its CHF 3.2 million in Series B Financing. ProteoMediX, in Schlieren, is a diagnostic company developing non-invasive diagnostic tests for the accurate detection, prognosis and therapy-selection of cancer. The round was led by Altos Venture, a Swiss venture capital firm chaired by Dr. Walter Fischli (co-founder of Actelion). The team at VISCHER is led by Matthias Staehelin (Corporate) with Roberto Peduzzi.